DDD (LON:DDD) (5.25p / £8.95m)
3D Diagnostics, which owns the protected rights to a technology platform with a number of significant potential commercial products, announced a distribution agreement with Wisdom International Medical Science and Technology Co. Ltd for China. The Company expects Wisdom to complete the regulatory approval process for sale of the CarieScan PRO later this year, with Wisdom having considerable experience in handling such a process- it is a subsidiary of Beijing Focus, which is one of the top 5 dental distributors in China focusing on imported technology products. Prospectively, this is a significant agreement since dental practitioners have increased more than ten-fold in the last 25 years to 60,000, with growth expected to continue in line with development of the Chinese economy.
AFC Energy (LON:AFC) (57.25p / £99.24m)
AFC Energy, a developer of alkaline fuel cells, has announced the signing of a commercial Memorandum of Understanding with John Lewis Partnership (JLP) to evaluate the economic potential of using its fuel cell system to generate low carbon emission electricity for Waitrose supermarkets and John Lewis stores. Following the evaluation, JLP intends to order and demonstrate AFC’s fuel cell system as part of an integrated low carbon energy generation at a Waitrose store.
Akers Biosciences (LON:AKR) (4.38p/ £7.38m)
Akers, the AIM listed provider of rapid diagnostic solutions for the point-of-care testing process, this week reported results for the year ended 31 December 2010. The company is also a pioneer in disposable breath condensate technology where there are a variety of wellness- and disease- predicting biomarkers present in an exhaled breath sample. Revenues increased by 72 per cent. to $3.1m (2009: $1.8m) with losses on an EBITDA basis cut by 84% to $649,000 (2009: $4.1m). Year end cash was down to $423, 000 but this was subsequently increased by a £2.16m placing in January 2011. The Company reported that 2010 was a very productive year for its new product pipeline and that moving in to 2011; it is well positioned to complete the clinical development of a number of novel rapid diagnostic testing solutions and introduce these products into high value markets, towards the end of the year and beyond.
Amur Minerals (LON:AMC) (11.88p / £29.73m)*
AIM listed exploration and development resource Company focused…
